Therapeutic options and treatment of muscle invasive bladder cancer

Expert Review of Anticancer Therapy

Volumn 1, Issue 4, 2001, Pages 511-522

  O'Connor, R Corey ^a   Alsikafi, Nejd F ^a   Steinberg, Gary D ^a  

^a WEISS MEMORIAL HOSPITAL   (United States)

Author keywords

Bladder cancer; Bladder preservation; Chemotherapy; Cystectomy; Invasive; P53; Partial cystectomy; Treatment

Indexed keywords

BCG VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

BLADDER CANCER; BLADDER MUSCLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; POSTOPERATIVE COMPLICATION; RADIATION BEAM; REVIEW; STANDARD; TRANSURETHRAL RESECTION; UROGENITAL TRACT CANCER;

EID: 0035558069     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.4.511     Document Type: Review

References (90)

1. Carcinoma of the bladder
2. Cancer statistics
3. Cancer statistics
4. Urothelial tumors of the urinary tract
5. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations
6. Surgical therapy for locally advanced bladder cancer
7. Malignant tumors of the urinary tract
8. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years
9. Multivariate analysis of progression in superficial bladder cancer
10. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence
11. Treated history of noninvasive grade 1 transitional cell carcinoma
12. Survival of patients with carcinoma in situ of the urinary bladder
13. Carcinoma in situ of the bladder
14. Cystectomy for bladder cancer, a contemporary series
15. Radical cystectomy in the treatment of invasive bladder cancer, long-term results in 1054 patients
16. Surgical treatment of urinary bladder cancer. Indications, techniques and general results
17. Study of survival after cystectomy for bladder cancer. Report of 504 cases
18. The impact of primary stage on survival in patients with lymph node positive bladder cancer
19. Predicting the survival of bladder carcinoma patients treated with radical cystectomy
20. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer, 10-year followup
21. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy
22. Pelvic lymph node metastases from bladder cancer, outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy
23. Clinical under staging of high-risk nonmuscle invasive urothelial carcinoma treated with radical cystecomy
24. Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma
25. Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion
26. Nerve-sparing cystectomy and substitution cystoplasty in patients of either sex, limitations and techniques
27. Recovery of sexual function after nerve-sparing radical prostatectomy or cystectomy
28. Complications of radical cystectomy and urinary diversion, A retrospective review of 675 cases in 2 decades
29. Complications for radical cystecomy. Impact of the American Society of Anesthesiologists score
30. Technique of Hautmann ileal neobladder with chimney modification, interim results in 50 patients
31. Bladder substitution after pelvic evisceration
32. Comparison of Studer ileal neobladder and ileal conduit urinary diversion with respect to perioperative outcome and late complications
33. Continent urinary reconstruction versus ileal conduit, A contemporary single-institution comparison of perioperative morbidity and mortality
34. Urinary diversion via a continent ileal reservoir, clinical results in 12 patients
35. Indiana continent urinary reservoir
36. The Indiana pouch continent urinary reservoir
37. Evolution of the Indiana continent urinary reservoir
38. Present experience with the Indiana pouch
39. Use of the Indiana-type continent reservoir, review of our series
40. Ureteroenteric anastomosis in continent urinary diversion, long-term results and complications of direct versus nonrefluxing techniques
41. Morbidity and quality of life in patients with orthotopic and heterotopic continent urinary diversion
42. The ileal neobladder
43. Female orthotopic bladder substitution. A good operation in the right circumstance
44. Orthotopic bladder substitution in women, functional evaluation
45. Choosing the right reconstruction for your female patients
46. Orthotopic lower urinary tract reconstruction in women using the Koch ileal neobladder, updated experience in 34 patients
47. Quality of life after cystectomy and urinary diversion: Results of a retrospective interdisciplinary study
48. The type of urinary diversion after radical cystectomy significantly impacts on the patient's quality of life
49. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?
50. The ileal neobladder, complications and functional results in 363 patients after 11 year follow-up
51. Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder, Prospective study
52. Transurethral resection of muscle-invasive bladder cancer, 10-year outcome
53. Is partial cystectomy the treatment of choice for mucinous adenocarcinoma of the urachus?
54. Partial cystectomy: An alternative to radical cystectomy?
55. Partial cystectomy for invasive bladder cancer
56. Partial cystecomy in the management of bladder carcinoma
57. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer
58. Efficacy of radio chemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer
59. Bladder preservation by combined modality therapy for invasive bladder cancer
60. Bladder sparing treatments for muscle invasive transitional cell carcinoma of the bladder
61. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder, a prospective study
62. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution Phase II study
63. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy, initial results of Radiation Therapy Oncology Group 89-03
64. The current status of bladder preservation in the treatment of muscle invasive bladder cancer
65. Against bladder sparing, surgery
66. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer
67. Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radio chemotherapy
68. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire
69. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy
70. Complications and results after cystectomy in male and female patients with locally invasive bladder cancer
71. Salvage cystectomy after radical irradiation for bladder cancer - Prognostic factors and complications
72. Complications of cystectomy in patients with a history of pelvic radiation
73. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases, a Southwest Oncology Group Study
74. Bladder preservation by combined modality therapy for invasive bladder cancer
75. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC intercontinental trial
76. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy, Nordic Cystectomy Trial I
77. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder, a prospective randomized Phase III study
78. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer. A randomized controlled trial
79. Randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer
80. Chemotherapy of metastatic bladder cancer
81. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium
82. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer, a prospective comparative trial
83. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2), Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study
84. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer
85. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer, results of a large, randomized, multinational, multicenter, Phase III study
86. Accumulation of nuclear p53 and tumor progression in bladder cancer
87. Can p53 help select patients with invasive bladder cancer for bladder preservation?
88. p53 and treatment of bladder cancer
89. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer
90. p53 in bladder cancer, mechanism of action, prognostic value and target for therapy